Molecular Imaging: Page 82

PET/MRI shows prowess for nodal staging in breast cancer

By Amerigo Allegretto

Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSNMMI01-4 | Room TBAIn this presentation, researchers will compare nodal staging between CT, MRI, and FDG-PET/MRI in patients with newly diagnosed breast cancer.

November 15, 2021

Combining radiomics, AI with PET/MRI helps assess nodal status

By Amerigo Allegretto

Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSNMMI01-3 | Room TBAHere, researchers will talk about how applying radiomics and machine learning to FDG-PET/MRI can noninvasively assess nodal status and treatment planning for breast cancer patients.

November 15, 2021

Combining radiomics, AI with PET/MRI helps assess nodal status

By Amerigo Allegretto

Sunday, November 28 | 10:30 a.m.-11:30 a.m. | SSNMMI01‐3 | Room TBAHere, researchers will talk about how applying radiomics and machine learning to FDG-PET/MRI can noninvasively assess nodal status and treatment planning for breast cancer patients.

November 14, 2021

Sofie receives nod to start trial for PET tracer

By AuntMinnie.com staff writers

Sofie Biosciences recently received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a clinical trial for a PET radiotracer based on fibroblast activation protein inhibitor.

November 11, 2021

ANSTO to partner with Cyclotek on theranostics facility

By AuntMinnie.com staff writers

The Australian Nuclear Science and Technology Organisation (ANSTO) is entering into a joint venture with Cyclotek to build a new theranostics facility in Melbourne.

November 11, 2021

Clarity hits milestone in study of radiopharmaceutical

By AuntMinnie.com staff writers

Clarity Pharmaceuticals, the Australian-based radiopharmaceutical developer, has completed patient recruitment in the dosimetry phase of a study of its theranostic agent with copper-based radioisotopes for treating metastatic castration-resistant prostate cancer.

November 11, 2021

How can the clinical potential of PET/MRI be unlocked?

By Frances Rylands-Monk

Why are some countries lagging behind others when it comes to unlocking the clinical potential of PET/MRI? Cancer imaging expert Dr. Vicky Goh of the U.K. took out her crystal ball and provided some insight into the future role of PET/MRI and how both modalities can be integrated effectively.

November 10, 2021

Subtle Medical nabs Vizient contract

By AuntMinnie.com staff writers

Artificial intelligence software developer Subtle Medical has secured a contract with group purchasing organization (GPO) Vizient to provide the GPO with MRI and PET image enhancement software.

November 9, 2021

Q BioMed partners with Eversana on Strontium89

By AuntMinnie.com staff writers

Biotech company Q BioMed has partnered with life sciences firm Eversana to support the commercialization of its Strontium89 therapeutic radiopharmaceutical in the U.S.

November 7, 2021

PET imaging lays foundation for new cancer therapies

By Will Morton

PET imaging of cancer patients with an experimental gallium-68 (Ga-68) tracer may be a reliable way to evaluate new therapies, according to a study published November 5 in the Journal of Nuclear Medicine.

November 7, 2021

CMS scrubs rule restricting PET tracer coverage

By Will Morton

The U.S. Centers for Medicare and Medicaid Services (CMS) has officially retired national noncoverage language from the books for PET imaging using radiopharmaceuticals for nononcologic indications.

November 4, 2021

Lantheus Q3 revenues grow, but so does net loss

By AuntMinnie.com staff writers

Lantheus Holdings reported revenue growth for the company's third quarter of fiscal 2021, but the company's net loss more than doubled.

November 4, 2021

Previous Page

Page 82 of 611

Next Page